Table 1.
Clinical and demographic characteristics
| Patients | Sex | Age | N° natalizumab infusions | EDSS at last natalizumab infusion | Anti-JCV index | Previous IS |
|---|---|---|---|---|---|---|
| Pt 1 | M | 37 | 52 | 1.5 | 1.1 | No |
| Pt 2 | M | 36 | 114 | 2.5 | 1.2 | No |
| Pt 3 | M | 26 | 19 | 1.5 | 1.5 | Yes |
| Pt 4 | F | 34 | 62 | 2.0 | 3.5 | Yes |
| Pt 5 | F | 57 | 91 | 3.5 | 2.3 | Yes |
| Pt 6 | F | 24 | 20 | 1.0 | 1.1 | No |
| Pt 7 | F | 26 | 85 | 6.5 | 0.4 | No |
| Pt 8 | F | 20 | 15 | 1.0 | 0.8 | No |
| Pt 9 | M | 46 | 19 | 3.0 | 2.0 | No |
| Pt 10 | M | 38 | 39 | 2.0 | 1.1 | Yes |
| Pt 11 | M | 44 | 12 | 1.5 | 3.5 | No |
| Pt 12 | F | 46 | 12 | 2.5 | 2.3 | No |
| Pt 13 | M | 22 | 12 | 2.0 | 3.1 | No |
| Pt 14 | F | 41 | 84 | 4.0 | 1.1 | No |
| Pt 15 | M | 48 | 18 | 5.0 | 2.3 | Yes |
| Pt 16 | F | 41 | 13 | 2.5 | 2.8 | No |
IS immunosuppressive therapy